Cart
sales@molnova.com
Rinucumab
CAS No. 1569263-06-4
Rinucumab( —— )
Catalog No. M36761 CAS No. 1569263-06-4
Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 453 | Get Quote |
|
| 5MG | 687 | Get Quote |
|
| 10MG | 937 | Get Quote |
|
| 25MG | 1371 | Get Quote |
|
| 50MG | 1812 | Get Quote |
|
| 100MG | 2421 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRinucumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionRinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.
-
DescriptionRinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1569263-06-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Megan Cully, et al. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Nat Rev Drug Discov. 2014 Jul;13(7):487.?
molnova catalog
related products
-
Regorafénib N-oxyde ...
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
-
Axitinib
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.
-
GF109203X
GF109203X is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ, respectively.
